Back in 2012, Vertex Pharmaceuticals (NASDAQ:VRTX) changed thousands of lives when it won approval to market Kalydeco to treat cystic fibrosis patients in the U.S. and EU. Cystic fibrosis, or CF, can be caused by one of many mutations Continue reading Vertex Turns Up the Heat on Cystic Fibrosis Challengers
Spending on pharmaceuticals is surging again, up 13% in 2014. Surveys show the public is increasingly concerned about the affordability of drugs. Part of the reason for their high costs is the advent of precision (or personalized) medicine, Continue reading The High Cost—and Difficult Ethics—of Personalized Medicine
$259,000 Drug Hard To Swallow For Some Patients
Re-posted here from KPBS website
Cystic Fibrosis Foundation
Posted on: 21 Jul 15
Today, the Cystic Fibrosis Foundation announced the launch of its fully redesigned website, www.cff.org. The new site reflects the Foundation’s ongoing commitment to provide people with CF the support, tools and information they need to live long and Continue reading CF Foundation Launches Fully Redesigned Website to Meet the Evolving Needs of People with CF and their Families
Originally published in the Boston Globe: https://www.bostonglobe.com/business/2015/07/20/researcher-and-group-doctors-challenge-vertex-price-new-cystic-fibrosis-drug/d5PZMlj6T6uzq0usm2xLEL/story.html#
By Robert Weisman Globe Staff
California scientist Paul M. Quinton learned that he has cystic fibrosis at age 19 and has spent his long career in his lab working on ways to cure it. Continue reading Doctors challenge Vertex over high price of cystic fibrosis drug
• The FDA should see a favorable benefit-to-risk ratio for KALYDECO in children of ages 2-5.
• Positive Phase 3 trials in patients with the most common CF mutation should also be enough for approval. This will triple the current addressable CF market. Continue reading Vertex Should Expect Approvals For Its Cystic Fibrosis Medications
Phase 3 Trial with VX-661 and VX-770 in CF Patients Homozygous DeltaF508 Now Enrolling!